Angela Hartley Brodie (28 September 1934 – 7 June 2017) was a British biochemist who pioneered development of steroidal aromatase inhibitors in cancer research.

Born in Lancashire (now Greater Manchester), Brodie studied chemical pathology to a doctoral level in Sheffield and was awarded a fellowship sponsored by National Institutes of Health.

After 17 years of working in Shrewsbury, Massachusetts on oral contraceptives with Harry Brodie, whom she married, she switched focus to the effects of the oestrogen-producing enzyme, aromatase, on breast cancer.

[3][7] As a result of her doctorate, she was awarded a National Institutes of Health sponsored, 1-year post-doctoral training fellowship, at Clark University and the Worcester Foundation for Experimental Biology in Shrewsbury, Massachusetts.

[3] When Brodie returned to work in 1971, she joined her husband's lab as staff scientist, moving into breast cancer research, especially its link with oestrogen and an enzyme that produces it, aromatase.

[8] Later she became Professor of Pharmacology and Experimental Therapeutics along with an appointment in the Department of Physiology[9] and a researcher role in the University of Maryland Greenebaum Cancer Center.

[9] She presented a paper on her aromatase inhibitors at a Rome conference in 1980, which led to collaboration with Charles Coombes, a British oncologist to start clinical trials on the inhibitor–4-hydroxyandrostenedione (4-OHA) in Royal Marsden Hospital.